CHAMBERLAIN UNIVERSITY | COLLEGE OF NURSING NR568 Advanced Pharmacology
Final Exam
NR568 / NR 568
Advanced Pharmacology for the Adult-Gerontology
Primary Care Nurse Practitioner
Questions with Comprehensive Answers & Rationales
Latest Update
Aligned with Chamberlain University NR568 Curriculum & AGPCNP Certification Competencies
Total Questions 120 (multiple choice, single best answer)
Sections 7 (OB/GYN, Infectious Disease, Psych/Neuro, Endocrine, Uro/Derm/Eye, Emergency/Special Pop
Cognitive Mix 25% Recall | 50% Application | 25% Analysis
Question Style 75% scenario-based | 15% direct recall | 10% clinical analysis
Passing Score 70%
Time Allotted 180 minutes (recommended)
Blueprint Source Chamberlain University NR568 Final Exam Blueprint (2026-2027)
Instructions to the Candidate
This comprehensive final examination assesses your mastery of advanced pharmacology principles required for
safe, evidence-based prescriptive practice as an Adult-Gerontology Primary Care Nurse Practitioner. Each item
presents four options (A-D); select the single best answer. Rationales accompanying each question incorporate
pharmacokinetic and pharmacodynamic principles, current ACOG / CDC / IDSA / GINA / ATS / ADA /
NAMS guideline recommendations, FDA boxed warnings, and Chamberlain NR568 course competencies
updated for the 2026-2027 academic cycle. Use the rationales as a study scaffold for AGPCNP board
preparation. A minimum score of 70% is required to pass.
Section Blueprint
Section Topic Domain Q Range #
1 Obstetric & Gynecologic Pharmacology Q1 - Q25 25
Final Exam - 120 Questions with Comprehensive Rationales - Curriculum Update
,CHAMBERLAIN UNIVERSITY | COLLEGE OF NURSING NR568 Advanced Pharmacology
2 Infectious Disease Pharmacology Q26 - Q55 30
3 Psychiatric & Neurologic Pharmacology Q56 - Q70 15
4 Endocrine & Metabolic Pharmacology Q71 - Q85 15
5 Urologic, Dermatologic & Ophthalmic Q86 - Q95 10
6 Emergency, Urgent Care & Special Populations Q96 - Q110 15
7 Integrated Clinical Case Scenarios Q111 - Q120 10
TOTAL 120
Final Exam - 120 Questions with Comprehensive Rationales - Curriculum Update
,NR568 - Advanced Pharmacology Final Exam AGPCNP - Chamberlain University - 2026/2027
Section 1: Obstetric and Gynecologic Pharmacology (Q1 - Q25)
Prenatal Care, Pregnancy Complications, Menopause, Hormone Therapy, Contraception
Q1. A 32-year-old primigravida at 12 weeks gestation presents for her first prenatal visit. The patient
asks when she can first expect to feel fetal movement. Based on NR568 fetal development milestones,
what is the correct anticipatory guidance for this primipara?
A. Quickening occurs at 14-18 weeks for a B. Quickening occurs at 18-20 weeks for a
primipara. primipara.
C. Fetal heart tones are audible by D. Quickening occurs at 22-24 weeks for a
Doppler at 14-16 weeks. primipara.
Correct Answer: B. Quickening occurs at 18-20 weeks for a primipara. [CORRECT]
Rationale: Per NR568 milestones, quickening (maternal perception of fetal movement) occurs at 18-20
weeks in a primipara and 14-18 weeks in a multigravida, reflecting the multiparous patient's prior
recognition of the sensation. Fetal heart tones become audible by Doppler at 10-12 weeks, earlier than
quickening because Doppler ultrasonography detects cardiac motion directly rather than relying on
maternal perception. The 14-18 week value describes the multigravida, while 22-24 weeks is well beyond
expected and would warrant evaluation for decreased fetal movement.
Q2. A patient at 11 weeks gestation undergoes first-trimester combined screening. Which serum
analytes are paired with the ultrasound nuchal translucency measurement in this screen?
A. Maternal serum alpha-fetoprotein B. Pregnancy-associated plasma protein A
(AFP) and unconjugated estriol. (PAPP-A) and beta-hCG.
C. Inhibin A and beta-hCG. D. AFP, beta-hCG, unconjugated estriol,
and inhibin A.
Correct Answer: B. Pregnancy-associated plasma protein A (PAPP-A) and beta-hCG. [CORRECT]
Rationale: First-trimester combined screening (performed at 11-14 weeks) pairs the fetal nuchal
translucency ultrasound with two maternal serum analytes: PAPP-A (typically decreased in trisomy 21)
and free beta-hCG (typically elevated in trisomy 21). The four-analyte quadruple screen (AFP, beta-hCG,
unconjugated estriol, inhibin A) is performed in the second trimester at 15-18 weeks. Mixing the two
panels is a common NR568 testing error.
Final Exam - 120 Questions - Passing Score: 70% Page 3
, NR568 - Advanced Pharmacology Final Exam AGPCNP - Chamberlain University - 2026/2027
Q3. A 27-year-old pregnant patient at 16 weeks gestation is scheduled for maternal serum screening.
The quadruple screen includes which four analytes?
A. AFP, beta-hCG, unconjugated estriol, B. PAPP-A, beta-hCG, unconjugated
inhibin A. estriol, inhibin A.
C. AFP, PAPP-A, beta-hCG, D. AFP, beta-hCG, estriol, CA-125.
unconjugated estriol.
Correct Answer: A. AFP, beta-hCG, unconjugated estriol, inhibin A. [CORRECT]
Rationale: The second-trimester quadruple screen (15-18 weeks) consists of AFP, beta-hCG,
unconjugated estriol, and inhibin A. PAPP-A is a first-trimester marker only. Elevated AFP suggests open
neural tube defect or underestimated gestational age; low AFP with elevated beta-hCG and inhibin A and
low estriol is the classic pattern of trisomy 21. CA-125 is an ovarian cancer marker, not part of
aneuploidy screening.
Q4. A 39-year-old G2P1 at 11 weeks gestation desires the earliest possible definitive chromosomal
diagnostic testing. The AGPCNP correctly counsels her that chorionic villus sampling (CVS) can be
performed during which gestational window?
A. 8-10 weeks. B. 10-13 weeks.
C. 15-20 weeks. D. 24-28 weeks.
Correct Answer: B. 10-13 weeks. [CORRECT]
Rationale: CVS is performed at 10-13 weeks and provides a direct chromosomal karyotype from placental
chorionic villi, allowing the earliest definitive diagnosis of fetal aneuploidy. Amniocentesis, the
alternative diagnostic test, is performed later at 15-20 weeks. Performing CVS before 10 weeks is
associated with limb-reduction defects and is therefore avoided. The 24-28 week window corresponds to
gestational diabetes screening, not diagnostic genetic testing.
Q5. A patient declines CVS and prefers amniocentesis. At which gestational age is amniocentesis
traditionally performed for fetal karyotyping?
A. 9-11 weeks. B. 12-14 weeks.
C. 15-20 weeks. D. 22-26 weeks.
Correct Answer: C. 15-20 weeks. [CORRECT]
Rationale: Amniocentesis for fetal karyotyping is performed at 15-20 weeks, when there is sufficient
amniotic fluid and the risk of procedure-related pregnancy loss (<0.5%) and talipes equinovarus is
minimized. Performing amniocentesis before 15 weeks increases the risk of fetal loss and musculoskeletal
anomalies. CVS remains the only earlier option for definitive diagnosis.
Final Exam - 120 Questions - Passing Score: 70% Page 4
Final Exam
NR568 / NR 568
Advanced Pharmacology for the Adult-Gerontology
Primary Care Nurse Practitioner
Questions with Comprehensive Answers & Rationales
Latest Update
Aligned with Chamberlain University NR568 Curriculum & AGPCNP Certification Competencies
Total Questions 120 (multiple choice, single best answer)
Sections 7 (OB/GYN, Infectious Disease, Psych/Neuro, Endocrine, Uro/Derm/Eye, Emergency/Special Pop
Cognitive Mix 25% Recall | 50% Application | 25% Analysis
Question Style 75% scenario-based | 15% direct recall | 10% clinical analysis
Passing Score 70%
Time Allotted 180 minutes (recommended)
Blueprint Source Chamberlain University NR568 Final Exam Blueprint (2026-2027)
Instructions to the Candidate
This comprehensive final examination assesses your mastery of advanced pharmacology principles required for
safe, evidence-based prescriptive practice as an Adult-Gerontology Primary Care Nurse Practitioner. Each item
presents four options (A-D); select the single best answer. Rationales accompanying each question incorporate
pharmacokinetic and pharmacodynamic principles, current ACOG / CDC / IDSA / GINA / ATS / ADA /
NAMS guideline recommendations, FDA boxed warnings, and Chamberlain NR568 course competencies
updated for the 2026-2027 academic cycle. Use the rationales as a study scaffold for AGPCNP board
preparation. A minimum score of 70% is required to pass.
Section Blueprint
Section Topic Domain Q Range #
1 Obstetric & Gynecologic Pharmacology Q1 - Q25 25
Final Exam - 120 Questions with Comprehensive Rationales - Curriculum Update
,CHAMBERLAIN UNIVERSITY | COLLEGE OF NURSING NR568 Advanced Pharmacology
2 Infectious Disease Pharmacology Q26 - Q55 30
3 Psychiatric & Neurologic Pharmacology Q56 - Q70 15
4 Endocrine & Metabolic Pharmacology Q71 - Q85 15
5 Urologic, Dermatologic & Ophthalmic Q86 - Q95 10
6 Emergency, Urgent Care & Special Populations Q96 - Q110 15
7 Integrated Clinical Case Scenarios Q111 - Q120 10
TOTAL 120
Final Exam - 120 Questions with Comprehensive Rationales - Curriculum Update
,NR568 - Advanced Pharmacology Final Exam AGPCNP - Chamberlain University - 2026/2027
Section 1: Obstetric and Gynecologic Pharmacology (Q1 - Q25)
Prenatal Care, Pregnancy Complications, Menopause, Hormone Therapy, Contraception
Q1. A 32-year-old primigravida at 12 weeks gestation presents for her first prenatal visit. The patient
asks when she can first expect to feel fetal movement. Based on NR568 fetal development milestones,
what is the correct anticipatory guidance for this primipara?
A. Quickening occurs at 14-18 weeks for a B. Quickening occurs at 18-20 weeks for a
primipara. primipara.
C. Fetal heart tones are audible by D. Quickening occurs at 22-24 weeks for a
Doppler at 14-16 weeks. primipara.
Correct Answer: B. Quickening occurs at 18-20 weeks for a primipara. [CORRECT]
Rationale: Per NR568 milestones, quickening (maternal perception of fetal movement) occurs at 18-20
weeks in a primipara and 14-18 weeks in a multigravida, reflecting the multiparous patient's prior
recognition of the sensation. Fetal heart tones become audible by Doppler at 10-12 weeks, earlier than
quickening because Doppler ultrasonography detects cardiac motion directly rather than relying on
maternal perception. The 14-18 week value describes the multigravida, while 22-24 weeks is well beyond
expected and would warrant evaluation for decreased fetal movement.
Q2. A patient at 11 weeks gestation undergoes first-trimester combined screening. Which serum
analytes are paired with the ultrasound nuchal translucency measurement in this screen?
A. Maternal serum alpha-fetoprotein B. Pregnancy-associated plasma protein A
(AFP) and unconjugated estriol. (PAPP-A) and beta-hCG.
C. Inhibin A and beta-hCG. D. AFP, beta-hCG, unconjugated estriol,
and inhibin A.
Correct Answer: B. Pregnancy-associated plasma protein A (PAPP-A) and beta-hCG. [CORRECT]
Rationale: First-trimester combined screening (performed at 11-14 weeks) pairs the fetal nuchal
translucency ultrasound with two maternal serum analytes: PAPP-A (typically decreased in trisomy 21)
and free beta-hCG (typically elevated in trisomy 21). The four-analyte quadruple screen (AFP, beta-hCG,
unconjugated estriol, inhibin A) is performed in the second trimester at 15-18 weeks. Mixing the two
panels is a common NR568 testing error.
Final Exam - 120 Questions - Passing Score: 70% Page 3
, NR568 - Advanced Pharmacology Final Exam AGPCNP - Chamberlain University - 2026/2027
Q3. A 27-year-old pregnant patient at 16 weeks gestation is scheduled for maternal serum screening.
The quadruple screen includes which four analytes?
A. AFP, beta-hCG, unconjugated estriol, B. PAPP-A, beta-hCG, unconjugated
inhibin A. estriol, inhibin A.
C. AFP, PAPP-A, beta-hCG, D. AFP, beta-hCG, estriol, CA-125.
unconjugated estriol.
Correct Answer: A. AFP, beta-hCG, unconjugated estriol, inhibin A. [CORRECT]
Rationale: The second-trimester quadruple screen (15-18 weeks) consists of AFP, beta-hCG,
unconjugated estriol, and inhibin A. PAPP-A is a first-trimester marker only. Elevated AFP suggests open
neural tube defect or underestimated gestational age; low AFP with elevated beta-hCG and inhibin A and
low estriol is the classic pattern of trisomy 21. CA-125 is an ovarian cancer marker, not part of
aneuploidy screening.
Q4. A 39-year-old G2P1 at 11 weeks gestation desires the earliest possible definitive chromosomal
diagnostic testing. The AGPCNP correctly counsels her that chorionic villus sampling (CVS) can be
performed during which gestational window?
A. 8-10 weeks. B. 10-13 weeks.
C. 15-20 weeks. D. 24-28 weeks.
Correct Answer: B. 10-13 weeks. [CORRECT]
Rationale: CVS is performed at 10-13 weeks and provides a direct chromosomal karyotype from placental
chorionic villi, allowing the earliest definitive diagnosis of fetal aneuploidy. Amniocentesis, the
alternative diagnostic test, is performed later at 15-20 weeks. Performing CVS before 10 weeks is
associated with limb-reduction defects and is therefore avoided. The 24-28 week window corresponds to
gestational diabetes screening, not diagnostic genetic testing.
Q5. A patient declines CVS and prefers amniocentesis. At which gestational age is amniocentesis
traditionally performed for fetal karyotyping?
A. 9-11 weeks. B. 12-14 weeks.
C. 15-20 weeks. D. 22-26 weeks.
Correct Answer: C. 15-20 weeks. [CORRECT]
Rationale: Amniocentesis for fetal karyotyping is performed at 15-20 weeks, when there is sufficient
amniotic fluid and the risk of procedure-related pregnancy loss (<0.5%) and talipes equinovarus is
minimized. Performing amniocentesis before 15 weeks increases the risk of fetal loss and musculoskeletal
anomalies. CVS remains the only earlier option for definitive diagnosis.
Final Exam - 120 Questions - Passing Score: 70% Page 4
